Clinical Study

A Pilot Feasibility Study In The Detection And Monitoring Of Minimal Residual Disease In The Blood Of Patients Undergoing Treatment For High-Grade B Cell Lymphomas Including Diffuse Large B Cell Lymphoma (Dlbcl), C-Myc-Positive Dlbcl And Burkitt’S Ly

Posted Date: Sep 9, 2017

  • Investigator: John Morris
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Observational/Survey

The purpose of this research study is to learn how tumor cells can be detected from blood as a marker of the activity of your disease.


To Be Eligible To Participate, Patients Must Have Been Diagnosed With Diffuse Large B Cell No-Hodgkin's Lymphoma (Dlbcl Nhl), C-Myc-Positive Dlbcl Or Burkitt's Lymphoma


Lymphoma, Ucci-Hem-15-01, Hematologic Malignancy , Phase I, Diffuse Large B Cell Lymphoma

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.